Print

Print


Current management of motor fluctuations in patients
with advanced Parkinson's disease treated chronically with levodopa.

Motor fluctuations after long-term administration of levodopa may be due to
central pharmacodynamic mechanisms such as reduced striatal synthesis and
storage of dopamine from exogenous levodopa and subsensitization of
postsynaptic dopaminergic receptors.

Peripheral pharmacokinetic mechanisms may be equally important,
particularly in motor fluctuations of the "delayed on" (increased time
latencies from dose intake to start-up of clinical benefit) and "no-on"
(complete failure of a levodopa dose to exert an "on" response) types.

Levodopa itself has a very poor solubility.

In addition, there is delayed gastric emptying in many advanced patients.

Therefore, an oral dose of levodopa may remain in the stomach for long
periods of time before it passes into the duodenum where there is immediate
absorption.

Consequently, in order to overcome response fluctuations caused by impaired
pharmacokinetic mechanisms and to improve its absorption, we recommend that
levodopa be taken in multiple small doses, on an empty stomach, preferably
crushed and mixed with a lot of liquid. Protein intake should be minimized.

Prokinetic drugs such as prepulsid (Cisaprid) could be used to facilitate
gastric motility and levodopa transit time.

Administration of crushed levodopa through nasoduodenal or
gastrojejunostomy tubes may be helpful in certain circumstances.

Bypassing the stomach with subcutaneous injections of apomorphine may
provide dramatic rescue from difficult "off" situations.

Oral and s.c. administration of novel, extremely soluble prodrugs of
levodopa, e.g., levodopa ethylester, may offer a new approach to overcome
difficulties in levodopa absorption.

Addition of dopamine agonists, MAO-B inhibitors, COMT inhibitors and
controlled release levodopa preparations may be helpful in prolonging the
duration of efficacy of each single levodopa dose.

Levodopa, administered orally, usually combined with peripheral dopa
decarboxylase inhibitors, continues to be the most widely-used and most
effective pharmacological treatment for Parkinson's disease (Melamed, 1987).

Undoubtedly, the outstanding therapeutic success of levodopa represents a
dramatic and revolutionary breakthrough in medicine, in general, and in
neurology, in particular.

Although, since the introduction of levodopa, there have been many
additional pharmacological and even surgical anti-parkinsonian strategies,
it still stands out as a mandatory axis of treatment in the majority of
patients (Steigler and Quinn, 1992).

Indeed, levodopa therapy improves, sometimes markedly, the motor signs and
symptoms of the illness, the functional capacity and quality of life and
perhaps also life expectancy of the afflicted patients.

It is therefore unfortunate that after an initial problem-free period of
successful, smooth and stable clinical benefit from levodopa that lasts
about two to five years, the responsiveness of many patients worsens with
the emergence of a variety of complications (Marsden et al., 1982; Hardie
et al., 1984).

These adverse reactions include dyskinesias and dystonias, psychotic
problems and, particularly, the troublesome motor fluctuations (Marsden and
Parkes, 1977; Marsden, 1994).

The latter phenomenon may be particularly complex, limiting and disabling.

It is believed that most patients on long-term levodopa therapy will,
sooner or later, develop response fluctuations of varying types and
severity (Riley and Lang, 1993).

Because of the serious impact of these phenomena on the quality of life and
function of the patients, many efforts are now being undertaken to identify
the responsible mechanisms and to devise preventive and therapeutic measures.


J Neural Transm Suppl 1999;56:173-83
Melamed E, Zoldan J, Galili-Mosberg R, Ziv I, Djaldetti R
Department of Neurology, Rabin Medical Center, Petah Tikva, Israel.
PMID: 10370911, UI: 99299049
<http://www.ncbi.nlm.nih.gov/PubMed>

janet paterson
52 now / 41 dx / 37 onset
PO Box 171  Almonte  Ontario  K0A 1A0  Canada
a new voice http://www.geocities.com/SoHo/Village/6263/
[log in to unmask]